Based on the key indicators related to Syndax Pharmaceuticals' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Syndax Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Syndax Pharmaceuticals' Short Term Investments are fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 643.5 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 1.6 M in 2024. Key indicators impacting Syndax Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Syndax Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Syndax Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Syndax Pharmaceuticals.
Please note, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Check Syndax Pharmaceuticals' Beneish M Score to see the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
Syndax Pharmaceuticals Stock Summary
Syndax Pharmaceuticals competes with Candel Therapeutics, Unicycive Therapeutics, Cardio Diagnostics, Virax Biolabs, and Senti Biosciences. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Syndax Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Syndax Pharmaceuticals. It measures of how well Syndax is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Syndax Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Syndax had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Syndax Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Syndax Pharmaceuticals competition to find correlations between indicators driving Syndax Pharmaceuticals's intrinsic value. More Info.
Syndax Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Syndax Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syndax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Syndax Pharmaceuticals Systematic Risk
Syndax Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Syndax Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Syndax Pharmaceuticals correlated with the market. If Beta is less than 0 Syndax Pharmaceuticals generally moves in the opposite direction as compared to the market. If Syndax Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Syndax Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Syndax Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Syndax Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Syndax Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Syndax Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Syndax Pharmaceuticals growth as a starting point in their analysis.
Syndax Pharmaceuticals December 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Syndax Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Syndax Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Syndax Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Syndax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Syndax Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.